02.06.2024
Prevent & Delay
$55,923,322.00
85 months
The GPPAD-05 Study: Anti-Viral Action against Type 1 diabetes Autoimmunity (AVAnT1A)
Funding supports a randomized, placebo-controlled primary prevention clinical trial for type 1 diabetes.